Undisclosed GBM therapeutic / Pathios Therap - LARVOL DELTA

Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer (PRNewswire) - "Pathios Therapeutics Limited...announced that the company has been awarded a £567K (~US$727K) grant from Innovate UK, the UK government's innovation agency. The grant funding will enable the company to expand its development of novel small molecule GPR65 inhibitors into the area of a possible treatment of malignant brain tumors. The project is being conducted in collaboration with researchers from the University of Nottingham and is focused on optimizing small molecule GPR65 inhibitors to penetrate the central nervous system (CNS) and evaluate those optimized compounds in preclinical models of brain cancer....With this grant, Pathios is utilizing an extensively developed proprietary assay platform to optimize CNS penetration of small molecule GPR65 inhibitors for the treatment of human malignant gliomas."

Financing • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology